GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BridgeBio Pharma Inc (FRA:2CL) » Definitions » Debt-to-Revenue

BridgeBio Pharma (FRA:2CL) Debt-to-Revenue : 158.26 (As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is BridgeBio Pharma Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

BridgeBio Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €4.1 Mil. BridgeBio Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €1,554.4 Mil. BridgeBio Pharma's annualized Revenue for the quarter that ended in Sep. 2024 was €9.8 Mil. BridgeBio Pharma's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 was 158.26.


BridgeBio Pharma Debt-to-Revenue Historical Data

The historical data trend for BridgeBio Pharma's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BridgeBio Pharma Debt-to-Revenue Chart

BridgeBio Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial 2.26 60.10 24.76 22.20 187.02

BridgeBio Pharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 106.04 249.29 2.05 199.42 158.26

Competitive Comparison of BridgeBio Pharma's Debt-to-Revenue

For the Biotechnology subindustry, BridgeBio Pharma's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BridgeBio Pharma's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BridgeBio Pharma's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where BridgeBio Pharma's Debt-to-Revenue falls into.



BridgeBio Pharma Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

BridgeBio Pharma's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(3.785 + 1591.646) / 8.531
=187.02

BridgeBio Pharma's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(4.145 + 1554.359) / 9.848
=158.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2024) Revenue data.


BridgeBio Pharma Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of BridgeBio Pharma's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


BridgeBio Pharma Business Description

Traded in Other Exchanges
Address
3160 Porter Drive, Suite 250, Palo Alto, CA, USA, 94304
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

BridgeBio Pharma Headlines

No Headlines